Neuronal antibody prevalence in children with seizures under 3 years: a prospective national cohort

Symonds, J. D. et al. (2020) Neuronal antibody prevalence in children with seizures under 3 years: a prospective national cohort. Neurology, 95(11), e1590-e1598. (doi: 10.1212/WNL.0000000000010318) (PMID:32690789)

[img] Text
218745.pdf - Accepted Version

527kB

Abstract

Objective: To report the prevalence of anti-neuronal antibodies in a prospectively whole nation cohort of children presenting with seizures before their third birthday. Methods: This was a prospective population-based national cohort study involving all children presenting with new onset epilepsy or complex febrile seizures before their 3rd birthday over a three-year period. Patients with previously identified structural, metabolic or infectious cause for seizures were excluded. Serum samples were obtained at first presentation and tested for seven neuronal antibodies using live cell-based assays. Clinical data were collected using structured proformas at recruitment, and 24 months after presentation. In addition, patients with seizures and clinically suspected autoimmune encephalitis were independently identified by reviewing the case records of all children < 3 years in Scotland who had undergone electroencephalography (EEG). Results: 298 patients were identified, recruited and underwent autoantibody testing. Antibody positivity was identified in 18/298 (6.0%). The antibodies identified were: GABABR (n = 8, 2.7%), CASPR2 (n = 4, 1.3%), GlyR (n = 3, 1.0%), LGI1 (n = 2, 0.7%), NMDAR (n = 1, 0.3%), and GABAAR (n = 1, 0.3%). None of these patients had a clinical picture of autoimmune encephalitis. Seizure classification and clinical phenotype did not correlate with antibody positivity. Conclusions: Autoimmune encephalitis is very rare in early childhood. However serum neuronal antibodies are identified in 6.4% of children presenting with seizures < 3 years. Antibody testing should not be a routine clinical test in early childhood-onset epilepsy as in the absence of other features of autoimmune encephalitis antibody-positivity is of doubtful clinical significance. Antibody testing should be reserved for patients with additional features of encephalitis.

Item Type:Articles
Additional Information:This study was supported by grants from Epilepsy Research UK and Dravet Syndrome UK.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Zuberi, Dr Sameer and Symonds, Dr Joseph and Dorris, Dr Liam and Brunklaus, Dr Andreas and Forbes, Dr Kirsten
Authors: Symonds, J. D., Moloney, T., Lang, B., McLellan, A., O'Regan, M., MacLeod, S., Jollands, A., Vincent, A., Kirkpatrick, M., Brunklaus, A., Shetty, J., Dorris, L., Forbes, K., Abu-Arafeh, I., Andrew, J., Brink, P., Callaghan, M., Cruden, J., Findlay, C., Grattan, R., MacDonnell, J., McKnight, J., Morrison, C. A., Nairn, L., Pilley, E., Stephen, E., Thomsen, S., Webb, A., Wilson, M., and Zuberi, S. M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Mental Health and Wellbeing
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Neurology
Publisher:American Academy of Neurology
ISSN:0028-3878
ISSN (Online):1526-632X
Published Online:20 July 2020
Copyright Holders:Copyright © 2020 American Academy of Neurology
First Published:First published in Neurology 95(11): e1590-e1598
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record